Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli

C Bantar; F Nicola; H J Arenoso; M Galas; L Soria; D Dana; A Rossi; H Bianchini; A Jasovich

doi:10.1128/AAC.43.6.1503

Pharmacokinetics and pharmacodynamics of amoxicillin-sulbactam, a novel aminopenicillin-beta-lactamase inhibitor combination, against Escherichia coli

Antimicrob Agents Chemother. 1999 Jun;43(6):1503-4. doi: 10.1128/AAC.43.6.1503.

Authors

C Bantar¹, F Nicola, H J Arenoso, M Galas, L Soria, D Dana, A Rossi, H Bianchini, A Jasovich

Affiliation

¹ Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina. bantar@drwebsa.com.ar

Abstract

We evaluated the pharmacokinetics of amoxicillin-sulbactam (AMX-SUL), a novel drug combination, and its pharmacodynamics against Escherichia coli in 12 volunteers receiving a single oral dose (1, 000 mg). Peak serum bactericidal and urine inhibitory activities in most volunteers were observed against E. coli strains for which AMX-SUL MICs were low (2- to 4-mg/liter) (2 strains) and high (>/=16-mg/liter) (47 strains), respectively.

MeSH terms

Adult
Amoxicillin / pharmacokinetics*
Amoxicillin / pharmacology
Drug Therapy, Combination / pharmacokinetics*
Drug Therapy, Combination / pharmacology
Enzyme Inhibitors / pharmacokinetics*
Escherichia coli / drug effects*
Female
Humans
Male
Middle Aged
Penicillins / pharmacokinetics*
Sulbactam / pharmacokinetics*
Sulbactam / pharmacology
beta-Lactamase Inhibitors*

Substances

Enzyme Inhibitors
Penicillins
beta-Lactamase Inhibitors
Amoxicillin
Sulbactam